43 results about "Cefuroximum" patented technology

The invention provides a method for synthesizing 3-decarbamoyl-acetyl-cefuroxin acid compound, comprising: using 2-(2-furyl)-2-oxo-acetaldehyde, 7-aminocephalosporanic acid , and methoxyamine as a raw material; under the joint action of the first catalyst, the oxidizing agent and the second catalyst, the raw material is reacted in a reaction solvent; Cefuroxime Acid Compound. Using the method of the invention, the process steps are simple, the by-product is mainly water, there will not be a large amount of remaining waste, and the cost of subsequent treatment and environmental protection pressure are low.

The invention relates to a cefuroxime sodium raw material, an injection and a preparation method thereof, belonging to the technical field of medicine. The cefuroxime sodium raw material of the present invention is passed in a specific solvent environment, with a special dropping rate, dropwise adding cefuroxime acid solution and a 95% ethanol solution of sodium acetate trihydrate prepared according to a specific mixed solvent ratio and a specific concentration at the same time Prepared. The product quality and stability of cefuroxime sodium for injection prepared from this raw material through special process control has been significantly improved, especially the production of related substance 2 has been reduced, and the product quality has been strictly controlled, thereby ensuring the safety and effectiveness of the drug.

The invention relates to an environmentally-friendly preparation method of an intermediate of cefuroxime acid. The method comprises the following steps: preparing an SMIA acyl chloride solution by utilizing triphosgene, preparing a D-7-ACA solution, and performing a condensation reaction on the SMIA acyl chloride solution and D-7-ACA solution to obtain DCC. The environmentally-friendly preparationmethod of the intermediate of the cefuroxime acid provided by the invention greatly reduces the amount of a chloride salt and a phosphate salt, and does not use high-boiling-point class-2 solvent dimethylacetamide (DMAC) difficult to recover and soluble in water, thereby greatly reducing environmental pressure, greatly reducing production costs, and steadily improving the product quality; the reaction for preparing the acyl chloride from the triphosgene is thorough, and the prepared acyl chloride has high purity, so that the prepared intermediate DCC also has higher purity; and the high-boiling-point class-2 solvent DMAC is not used; therefore the produced cefuroxime acid has a lower residual solvent, a residual solvent of bulk drug cefuroxime sodium and cefuroxime axetil produced by theintermediate of the cefuroxime acid is greatly reduced, the quality of the final product is better improved, and the yield is increased.

The invention relates to a cefuroxime lysine compound. The cefuroxime lysine contains 98-99.99% by weight of cefuroxime lysine and 0.01-2% of trans-cefuroxime acid, and the molecular formula of the trans-cefuroxime acid is as shown in formula I. The obtained cefuroxime lysine disclosed by the invention has very strong stability which is higher than that of the prior art; and the impurity content and the polymer content are lower than those of the cefuroxime lysine in the prior art, thus the cefuroxime lysine is very suitable for clinical applications.

The invention discloses a method for determining high-molecular polymers in cefuroxime axetil tablets, which comprises the following steps: the chromatographic conditions include a high-efficiency gel chromatographic column, the detector is UV, and the mobile phase is 0.03 mol / L lithium halide at 25- 35% N,N-dimethylformamide solution containing monoalcohols with 3 to 8 carbon atoms. The method of the present invention has better solution stability, can effectively prevent the degradation of the cefuroxime axetil component to be tested, and ensure the stability of the sample, so that the high molecular polymer in the cefuroxime axetil tablet can be more accurately controlled, and the product can be guaranteed. Quality, prevention of allergic reactions caused by polymers, and better protection of drug safety for patients.